Catena Biosciences

Using protein coupling to build new therapies

Y CombinatorSummer 2021ActiveHealthcareTherapeuticsBiotechTherapeutics

What they do

Problem

Developing protein-based therapeutics is slow and constrained by difficulty in reliably linking complex proteins without extensive engineering.

Solution

A protein-coupling platform that enzymatically attaches any two soluble proteins via native tyrosine and cysteine residues to rapidly build modular therapeutics.

Who it's for

Biopharma companies and research teams developing protein drugs, antibodies, vaccines, and gene-editing therapies.

Founders

Marco Lobba

Founder

CEO and Co-Founder at Catena Biosciences. Marco completed his Ph.D. at UC Berkeley jointly between the labs of Matt Francis and Jennifer Doudna. When not starting a company or doing science Marco likes to backpack, rock climb, kayak, and just about any activity that involves not being inside.